intravenous NEDD8-activating enzyme inhibitor
Ph. III candidate for oncology
from HTS and optimization
Drug Metab. Dispos.
Takeda, Lexington, MA
Pevonedistat
Context. Pevonedistat (Takeda) is a first-in-class intravenous or subcutaneous NEDD8-activating enzyme (NAE) inhibitor being developed for leukemia and advanced solid tumors. NAE is a pivotal regulator of the NEDD8…